The Professional and Luxurious Mirror of Manufacturing Dependency, Controlling Supply and Monetising the Return

When people hear the words drug dealer, they picture someone standing on a street corner, operating from a hidden flat or moving substances through an illegal network. They imagine cash, secrecy, addiction, intimidation and people returning because their bodies have become dependent upon what is being sold. When people hear the words technology mogul or pharmaceutical executive, they picture laboratories, headquarters, research departments, investor presentations, patents, regulators, medical conferences, smartphones and sophisticated global infrastructure.

One is treated as a danger to society.

The others are treated as builders of the future.

One is accused of creating dependency.

The others may call dependency retention, adherence, engagement, recurring revenue or lifetime customer value.

Yet when the decoration is removed, the commercial architecture can become uncomfortably similar.

All three understand that the most profitable customer is not always the person who purchases once.

It is the person who returns.

The street dealer wants repeat demand. The pharmaceutical company may benefit when treatment becomes continuous rather than temporary. The technology platform wants the user to reopen the application, refresh the feed, check the notification, respond to the prompt and return tomorrow. Each operates in a different legal, social and clinical environment, but the underlying commercial question can be the same:

How do we make departure less likely than return?

That is the first similarity: the product becomes most valuable when the customer’s relationship with it becomes difficult to end.

The dealer may sell a substance that creates chemical dependence.

The pharmaceutical company may sell a medicine that a patient genuinely needs, sometimes for life, but it may also operate within a commercial system that earns more from long-term symptom management than from prevention, cure or restoration. The technology company may sell no physical substance at all, yet design repeated behavioural stimulation through notifications, infinite scrolling, social approval, personalised recommendations and intermittent rewards.

One works through the bloodstream.

One works through the prescription.

One works through the nervous system and attention.

All three can learn how to occupy the interval between discomfort and relief.

The dealer identifies a craving and supplies the temporary answer.

The pharmaceutical industry identifies pain, illness, instability or biological dysfunction and supplies a regulated intervention.

The technology platform identifies boredom, loneliness, insecurity, curiosity, outrage or the desire for recognition and supplies another piece of content.

The conditions are not morally or medically identical. A prescribed medicine may save a life. A digital platform may provide education, employment, community and essential communication. The comparison is not an accusation that every medicine is poison or every application is equivalent to an illegal narcotic.

The comparison concerns the business model that emerges when relief is more profitable than resolution.

A responsible medicine supports health. A responsible technology supports human agency. The problem begins when the supplier benefits from keeping the customer close to the need that the product claims to address.

The street dealer says, directly or indirectly:

Come back when the effect wears off.

The pharmaceutical system may say:

Continue taking this indefinitely, while the causes surrounding the condition remain largely untouched.

The technology platform says:

You have something new to see.

Each message renews the relationship before the user has fully returned to equilibrium.

This is why all three industries study behaviour.

The dealer learns who is vulnerable, who has money, who is dependent, who is likely to return and who may introduce new customers.

The pharmaceutical company studies diagnosis rates, prescribing behaviour, treatment adherence, market access, patient retention and the decisions of healthcare professionals.

The technology company studies watch time, click-through rates, scrolling speed, emotional reactions, social graphs, purchasing patterns, location signals and the precise moment at which a person is likely to disengage.

On the street, this may be called knowing the customer.

In pharmaceuticals, it may be called market intelligence, patient adherence or treatment optimisation.

In technology, it is called behavioural analytics.

The language changes because legitimacy changes the interpretation of the same commercial intelligence.

The illegal dealer is condemned for understanding vulnerability well enough to exploit it.

The platform is celebrated for personalisation.

The pharmaceutical company is praised for identifying an underserved market.

Yet a market can be underserved because people need help, or attractive because their need is continuous. Those are not always the same motivation.

The pharmaceutical industry’s luxury mirror is built through institutional authority. The product does not arrive in a small plastic bag. It arrives in sealed packaging, supported by clinical language, professional guidance, dosage instructions, patents, reimbursement systems and regulatory approval. These structures matter because medicine requires testing, quality control and expert supervision. Legitimacy is not merely cosmetic.

But legitimacy does not eliminate commercial incentive.

A legal product may be necessary, effective and properly prescribed while still participating in a market that rewards prolonged consumption. A company may produce treatments of enormous public value while also lobbying to protect pricing, extending exclusivity, promoting narrow therapeutic solutions or investing more heavily in commercially attractive conditions than in illnesses affecting people with little purchasing power.

The white coat does not automatically remove the profit motive.

It professionalises the environment in which the motive operates.

The street dealer controls access through scarcity.

The pharmaceutical company may control access through patents, licensing, manufacturing rights, distribution agreements and pricing.

The technology mogul controls access through platforms, app stores, data ecosystems, operating systems, cloud infrastructure and algorithmic visibility.

All three understand that control over the route can become as valuable as control over the product.

The dealer may say:

You can only obtain it through me.

The pharmaceutical company may effectively say:

This treatment is protected, and access will occur on the terms established by the rights holder, healthcare system and insurer.

The technology platform may say:

You may reach your audience, customers, community or memories through infrastructure that we own and may alter.

Dependency is not created only by the substance.

It can be created by control of the pathway.

This is especially visible in technology because the substance being sold is often not the application itself.

The user may believe they are consuming content, but the platform is also consuming the user’s attention, behaviour and data. The person receives stimulation while the company receives a growing map of what stimulates them.

Every return teaches the system how to make the next return more likely.

The dealer learns through direct observation.

The platform learns at scale.

It can test different headlines, colours, sounds, timings, images and emotional triggers across millions of people. It can discover which form of outrage keeps someone watching, which insecurity makes them purchase, which notification interrupts concentration and which sequence of rewards creates habit.

The intelligence is automated, but the purpose remains recognisable:

Preserve the customer’s return.

The technology mogul therefore occupies a position the historical dealer could only have imagined. The dealer usually sells the dose. The platform can manufacture the craving, distribute the dose, measure the reaction, redesign the next dose and sell access to the person’s attention to advertisers.

It owns the laboratory, the street corner and the surveillance system at once.

The pharmaceutical industry has its own version of this vertical power. A company may participate in research, patent ownership, professional education, manufacturing, marketing, patient-support programmes and the evidence environment surrounding a treatment. None of these functions is automatically corrupt. Together, however, they can allow one commercial actor to influence how a condition is understood, which intervention is prioritised and how long the market remains attached to it.

The dealer does not need the customer to understand the chemistry.

They need the customer to trust the effect.

The technology company does not need the user to understand recommendation systems.

It needs the user to continue scrolling.

The pharmaceutical company does not need every patient to understand the wider economics of medicine.

It needs the treatment pathway to remain accepted.

In each case, information is unevenly distributed.

The supplier knows more about the product, the system and the intended behavioural outcome than the person receiving it.

That imbalance creates a duty of care.

Where knowledge and control increase, responsibility must increase with them.

Yet modern corporations often want the authority of expertise without accepting the full consequence of dependency. Technology companies may say that users choose how long they remain online. Pharmaceutical companies may say that prescribing decisions belong to clinicians. Platforms may blame creators. Manufacturers may blame misuse. Executives may point towards regulators, healthcare systems, parents or individual behaviour.

The modern pattern is familiar:

Own the product. Own the infrastructure. Own the revenue. Outsource the consequence.

The street dealer is rarely permitted such a sophisticated division of responsibility. Society traces the harm back to the person supplying the substance. In corporate systems, responsibility can be divided among departments, contractors, doctors, developers, advertisers, hospitals, governments and users until no one appears to hold the complete chain.

Scale becomes a shield.

Complexity becomes plausible deniability.

A person selling drugs illegally may be prosecuted for contributing to dependency in a neighbourhood.

A company may create dependency across continents and describe the outcome as market penetration.

A dealer may be condemned for targeting young or vulnerable people.

A platform may build a product accessible to children, study their attention and then describe parental control as the primary solution.

A dealer may be accused of encouraging repeated consumption.

A digital company may send reminders, streak warnings, personalised alerts and emotionally engineered prompts designed precisely to prevent interruption of use.

A dealer may offer the first experience cheaply to establish demand.

Technology companies offer free access while monetising behaviour later.

Pharmaceutical companies may provide introductory support, samples or patient-access arrangements within a system where long-term treatment becomes the larger commercial relationship.

Again, the existence of a similarity does not erase the differences. Medical samples can help patients begin necessary treatment. Free digital services can expand access. The question is what happens after entry.

Does the system strengthen the person’s independence, or deepen their dependence upon the system?

That is the moral measurement.

A treatment may require long-term use because the underlying condition is chronic and no cure exists. That is not exploitation by itself. A person may choose to spend hours online because they genuinely value the experience. That is not addiction by definition.

The danger begins when companies know that a product diminishes autonomy and continue optimising the very mechanisms responsible because those mechanisms increase revenue.

Knowledge changes responsibility.

The more precisely a company can measure dependency, the less honestly it can pretend that the outcome is accidental.

Technology companies know when users return, how often they wake during the night to check a device, which emotional states increase usage and where attempts to leave are abandoned.

Pharmaceutical companies collect extensive information about prescriptions, treatment persistence, adverse events, market performance and clinical outcomes.

The modern dealer does not merely know that the customer returned.

The modern dealer possesses dashboards explaining why.

This is also why the language of care must be examined carefully.

The pharmaceutical company may speak of patients while reporting to investors about market expansion.

The technology company may speak of community while measuring engagement.

The dealer may speak of friendship while preserving dependence.

In every case, relational language can conceal a commercial objective.

The customer is called a patient, user, member, follower or community participant.

The human being becomes easier to monetise once the transaction is described as a relationship.

This does not mean care is always false. Many scientists, doctors, pharmacists, developers and designers genuinely want to improve life. Some devote their careers to creating medicines, devices and technologies of extraordinary value. The critique is not directed at every person working inside these industries.

It is directed at systems that recruit human intelligence into architectures where commercial success can become separated from human recovery.

A researcher may develop a life-saving medicine.

An executive may price it beyond the reach of those who need it.

A developer may build a tool for connection.

A platform may optimise it for compulsion.

A doctor may prescribe responsibly.

A sales structure may pressure others to expand the market.

A medicine can heal while the surrounding business model remains predatory.

A platform can educate while its attention model remains extractive.

These truths can coexist.

The drug dealer comparison becomes most accurate where the organisation has no meaningful interest in the customer reaching the point at which the product is no longer needed.

A genuine healer wants the patient to recover, where recovery is medically possible.

A genuine educator wants the learner to become capable without them.

A genuine tool increases the user’s ability to act independently.

A dependency business does the opposite.

It makes absence feel like deprivation.

The customer begins to experience separation as discomfort.

Without the medicine, symptoms return.

Without the platform, boredom, anxiety or social disconnection emerges.

Without the digital ecosystem, work, memories, relationships or identity may feel inaccessible.

The body, mind or social life reorganises around continued supply.

This is the architecture of dependency, even where the dependency is not identical in severity, biology or consequence.

The dealer’s customer may chase the next dose.

The platform user chases the next notification.

The pharmaceutical patient may chase the next refill because withdrawal, symptom return or medical necessity makes interruption unsafe.

These are not interchangeable experiences, but each establishes power through continuity of supply.

That power demands different levels of regulation and care, not denial of the underlying resemblance.

The modern dealer has also improved the aesthetic of the transaction.

There is a pharmacy counter instead of a street corner.

There is a prescription instead of a whispered arrangement.

There is a clinical representative instead of a runner.

There is an app icon instead of a packet.

There is an algorithm instead of a lookout.

There is a notification instead of a phone call from a supplier.

There is a subscription instead of a tab.

There is a patent instead of territorial control.

There is an investor report instead of a cash count.

There is user growth instead of customer expansion.

There is treatment adherence instead of repeat business.

There is engagement instead of craving.

The language becomes cleaner while the dependency becomes more scalable.

Technology moguls and pharmaceutical corporations are not modern drug dealers simply because they sell technology or medicine. They become the luxurious mirror of drug dealing when they deliberately manufacture, deepen or preserve dependence while hiding behind professional legitimacy.

The distinction must remain precise.

Medicine that restores function is not the enemy.

Technology that expands human capacity is not the enemy.

The problem is the commercial architecture that discovers it can earn more from a person’s unresolved need than from their freedom.

The problem is a platform that designs for compulsion and then blames the user for lacking discipline.

The problem is a pharmaceutical system that neglects prevention because recurring treatment produces more dependable revenue.

The problem is an executive class that claims ownership over innovation but distributes responsibility for harm everywhere except upward.

The problem is not the existence of the dose.

It is the incentive to ensure the dose never ends.

This is why prevention is disruptive to dependency markets.

Prevention reduces the number of people entering the treatment pipeline.

Education reduces vulnerability to manipulation.

Strong public health reduces avoidable demand.

Digital literacy weakens behavioural capture.

Interoperability reduces dependence upon one technological supplier.

Repairability extends the life of devices.

Cures end markets.

Human autonomy is commercially inconvenient to any business that requires continuous need.

A responsible company should therefore be measured not only by how many people use its product, but by what condition those people are left in after using it.

Are they healthier?

Are they more capable?

Are they better informed?

Are they freer to leave?

Can they function without escalating consumption?

Has the product strengthened the person, or merely strengthened its position inside the person’s life?

The street dealer is judged by the devastation surrounding the product.

The modern corporation often asks to be judged only by the sophistication of the product itself.

That separation can no longer hold.

The greater the intelligence used to design dependence, the greater the duty to prevent it.

The greater the capacity to measure harm, the weaker the excuse for continuing it.

The greater the claim to improve humanity, the less acceptable it becomes to profit from humanity’s inability to disengage.

The modern drug dealer does not always wait in an alley.

Sometimes they stand on a stage announcing the next innovation.

Sometimes they sit before shareholders presenting recurring revenue.

Sometimes they wear a laboratory coat.

Sometimes they own the operating system.

Sometimes they say they are connecting the world.

Sometimes they say they are treating the patient.

But the defining question remains the same:

Does the system benefit when the person becomes well enough, secure enough or autonomous enough to leave?

Where the answer is no, the profession may be more polished, regulated and luxurious than street dealing.

The dependency model remains familiar.

The street dealer sells a substance and waits for the customer to return.

The pharmaceutical empire may sell continuing treatment and call the return adherence.

The technology empire sells stimulation and calls the return engagement.

Same dependency. Different distribution network.